A trial of one KRAS G12D inhibitor is halted early, while that of another sees tox troubles.
ApexOnco Front Page
Recent articles
The group’s first pivotal readout, in second-line pancreatic cancer, is coming.
Varegacestat’s pivotal study reads out imminently.
Readout of the Preserve-003 trial in post-PD-(L)1 NSCLC is due in December.
ASH and SABCS approach.
The project has priority review, but deaths could raise eyebrows.
New first-in-human trials include Kivu and Menarini projects acting on PKT7 and KIF18A.
An in vivo Car-T produced a 100% response rate – in three patients.
